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Room 158, Toronto, Ontario, Canada M5T 2S8Genotypes 2 and 3 (G2/G3) of hepatitis C virus have been together of G2 and G3 in clinical trials and scientiﬁc reports and
lumped together as ‘easy to treat’. As a result, guidelines recom-
mend 24 weeks of peginterferon/ribavirin for both. However, a
closer look at trials shows that these genotypes are not the same,
with G2 infection proving more responsive to peginterferon. The
data supporting this conclusion are presented along with possible
explanations for the differences observed. Ultimately, decisions
must be made about therapy. Rapid virological response (RVR)
may be the best parameter predicting successful antiviral ther-
apy. For patients with G2 infection who achieve an RVR, short-
ened courses of therapy are effective. In contrast, for G3
patients without an RVR, there may be beneﬁt to extending ther-
apy to 48 weeks; however, this requires conﬁrmation in prospec-
tive studies. Using RVR to guide therapy may level the playing
ﬁeld between these ‘easy to treat’ genotypes.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The current standard of care for patients with chronic hepatitis C
consists of pegylated interferon alpha (pegIFN) and ribavirin
(RBV), with duration of therapy and dosing of RBV varying
according to the genotype of the virus [1,2]. In patients with
genotypes 2 and 3 (G2/G3) the recommended therapy is a
24-week course with a reduced dose of RBV, achieving a sus-
tained virological response (SVR) in 75–80% of cases. This rate
of successful therapy highly contrasts with the 45–55% reported
for genotype 1 (G1), despite higher doses of therapy given for
48 weeks. The striking difference seemed to justify the groupingJournal of Hepatology 20
Keywords: Hepatitis C virus; Genotypes; Viral kinetics; Peginterferon; Ribavirin;
Prognostic factors; Insulin resistance.
Received 8 October 2010; received in revised form 28 January 2011; accepted 11
February 2011
⇑Corresponding author.
E-mail address: Jordan.Feld@uhn.on.ca (J.J. Feld).
Abbreviations: pegIFN, peginterferon; ribavirin, RBV; G, genotype (G1-4); SVR,
sustained virological response; HCV, hepatitis C virus; RVR/EVR, rapid/early v-
irological response; ALT, alanine aminotransferase; OR/95%CI, odds ratio/95%
conﬁdence interval; CHC, chronic hepatitis C; ISG, interferon-stimulated genes;
Jak/STAT, Janus kinase transducers and activators of transcription; SNP, single
nucleotide polymorphisms; IL28B, interleukin 28b; SREBPc, sterol regulatory
element-binding protein; MTP, microsomal triglyceride transfer.the early registration trials seemed to validate this approach [3].
However, a closer look at published trials suggests a clinically
meaningful difference in response to treatment between G2
and G3 and raises the question of whether it is in fact appropriate
to lump them together. Additionally, close inspection of the data
suggests that it may be appropriate to have different therapeutic
approaches for these different genotypes. Viral kinetics might be
a useful tool for tailoring the therapy to improve efﬁcacy.Predictors of viral eradication
Several viral and host factors have been shown to affect the
response to antiviral therapy (Fig. 1). Although most experience
derives from trials including predominantly patients with G1,
many aspects also apply to G2 and G3. The role played by each
factor in a given patient is almost impossible to dissect, but great
enthusiasm has recently been paid to viral kinetics. Given that
early viral kinetics are themselves a measure of treatment
response, it is not surprising that they predict ultimate treatment
outcome – response predicts response. As such, viral kinetics can
and should form the basis for most therapeutic decisions.
Ferenci et al. ﬁrst showed that the rapidity of HCV RNA
decline was of utmost importance for reaching an SVR, and a
therapeutic advantage was observed in patients achieving an
RVR (87%) when compared to those with a >2 log10 IU/ml
decrease but detectable levels at 4 weeks of treatment (52%)
[4]. More recent studies including patients with G1 infection have
conﬁrmed that the greater the viral suppression during the ﬁrst
4 weeks of therapy, the greater the likelihood of reaching an
SVR. In the Virahep-C study, Hoofnagle et al. found that early viral
kinetics were very useful, showing an increasing rate of SVR for
every 1 log10 decrease in the hepatitis C virus (HCV) RNA level
at 4 weeks into therapy (Table 1) [5].
Both the early virological response at 12 weeks of therapy
(EVR) and RVR have proven useful to tailor treatment in G1 infec-
tion, however, for slightly different purposes [6–8]. EVR has been
used to deﬁne the minimum necessary response for patients to
ultimately achieve an SVR. In other words, it has very good neg-
ative predictive value and thus is used to deﬁne treatment stop-
ping rules. In contrast, RVR is used for its positive predictive
value; achievement of RVR is highly predictive of SVR. RVR is a
useful predictor in G1 and may even allow for shortening of11 vol. 55 j 466–473
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Fig. 1. Factors associated with response to treatment in chronic hepatitis C
infection. Genetic factors such as IL28B genotype and hepatic gene expression
proﬁles are important host determinants of response. Metabolic factors such as
obesity, steatosis, insulin resistance, and type 2 diabetes mellitus also play an
important role.
Table 1. Relationship between the decrease in viral load after four weeks of
antiviral therapy and the rate of sustained virological response in the
Virahep-C study.
HCV RNA decrease n Rate of SVR
<1 log10 IU/ml 92 13 
1 to ≤2 log10 IU/ml 87 32 
2 to ≤3 log10 IU/ml 68 53 
3 to ≤4 log10 IU/ml 54 74 
40 85 
Negative (RVR) 60 77 
≥4 log10 IU/ml
G2- 24 wk
G2- short
G3- 24 wk
G3- short*
JOURNAL OF HEPATOLOGYtherapy to 24 weeks, but unfortunately it is a rare event, occur-
ring in only 15–30% of patients. In contrast, RVR is achieved in
60–80% of patients with G2 and G3 infection. With the shorter
duration of treatment, the high rate of RVR and the strong corre-
lation with subsequent SVR, RVR may be the most useful viral
kinetic parameter for tailoring the duration of antiviral therapy
in patients with G2 and G3 infection.0
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Fig. 2. Bar chart showing the sustained virological response rates in the
ACCELERATE (Shiffman et al.) and NORDynamIC (Lagging et al.) trials, which
focused on patients with G2/G3 infection. The results are shown according to
genotype and duration of treatment ⁄p value <0.01.Clinical trials with genotypes 2 and 3 assessing the RVR
Large clinical trials assessing the efﬁcacy of antiviral treatment
arbitrarily combined G2 and G3 patients, based on their under-
representation and higher rate of SVR when compared with G1
[3,9–12]. This has led to the false notion that G2 and G3 have a
similar rate of response to pegIFN and RBV, but a careful exami-
nation of the evidence would suggest otherwise.
Most studies, in which comparison is available, have found at
least a trend toward improved outcomes in patients with G2
compared to G3, although not surprisingly the differences in rates
of SVR are small between genotypes if patients achieve an RVR.
Larger differences emerge when comparing patients with slower
responses i.e. those who do not achieve an RVR. Because no study
has directly assessed the issue of G2 vs G3 as its primaryJournal of Hepatology 201endpoint, any conclusions based on genotype must be teased
out of studies assessing other factors.
A meta-analysis compared the results from trials between G2
and G3. Summarizing the experience from 8 studies including
2275 patients (not all randomized trials), patients with G2 had
a signiﬁcantly higher SVR rate (74%) when compared to G3
(69%), with a weighted difference of 8.7% (95% CI = 5.1–12.3)
and a pooled OR: 1.49 (95% CI = 1.23–1.80). Furthermore, in
patients with a high viral load (mostly deﬁned as >600,000
IU/ml) the respective SVR rates were 75% and 58%, and the
weighted difference rose to 24.9% (12.8–37) with an OR: 2.36
(95% CI = 1.80–3.09). Conﬁrming the importance of viral titer in
G3, they found that even in patients receiving the standard
24-week regimen who achieved an RVR, G3 patients with a high
baseline viral load experienced a lower rate of SVR (81%)
compared to those with G2 (94%). The weighted difference was
12.6% (95% CI = 1.3–23.9), with an OR: 2.94 (95% CI = 0.99–
8.72). The difference between genotypes was again more striking
in patients who did not achieve an RVR, with a pooled SVR rate
for G2 of 62%, compared to 46% for G3, for a weighted difference
of 17.8% (95% CI = 8.7–27) and an OR: 2.06 (95% CI = 1.4–3.02)
[13].
Examining data from landmark studies, differences between
G2 and G3 beyond absolute rates of SVR with standard therapy
emerge. The ACCELERATE study was a large (n = 1469) multina-
tional trial designed to assess if a shortened course of therapy
(16 weeks) was non-inferior to the standard duration (24 weeks).
As shown in Fig. 2 the SVR rate was different between the groups
receiving 24 and 16 weeks only in G2 patients. Notably, however,
the absolute difference in response at 24 weeks between G2 and
G3 was 9%. Multivariable analysis revealed that G2 infection was
independently associated with SVR along with 24 weeks of treat-
ment duration, low viral load (6800,000 IU/ml), age 645 years,
weight 680 kg, high ALT (>3 times the upper limit of normal)
and absence of bridging ﬁbrosis/cirrhosis. Importantly, however,
in a post hoc analysis they found that patients achieving an RVR
had a higher rate of SVR, independent of HCV genotype or treat-1 vol. 55 j 466–473 467
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ment duration [14]. The NORDynamIC trial compared 24 vs
12 weeks of treatment in 382 G2/3 patients. In this study,
24 weeks of therapy was superior, both for G2 and G3 and the
absolute difference between G2 and G3 treated for 24 weeks
was only 4%. However, patients with G2 infection were signiﬁ-
cantly older, perhaps explaining the reduced difference between
G2 and G3 when compared to ACCELERATE (Fig. 2). Multivariable
analysis identiﬁed RVR and age <40 years as predictors of SVR.
The presence of bridging ﬁbrosis/cirrhosis had a major impact
in decreasing the SVR rate, even in patients under the 24-week
regimen: 84% if non-signiﬁcant ﬁbrosis, 76% in bridging ﬁbrosis,
57% in cirrhosis [15]. The studies, both using 800 mg of RBV,
showed that shorter courses of therapy were not equivalent to
the 24 week standard and G2 patients fared at least somewhat
better than those with G3. As expected, RVR was a strong predic-
tor of subsequent SVR, regardless of genotype or treatment
duration.
To directly assess whether RVR can be used to determine the
length of therapy, randomized, open-label studies have assessed
the possibility of giving shortened courses of therapy to patients
who achieve an RVR. Fig. 3 shows the SVR rates in two of these
trials, and contrasts their results with the post hoc analysis of
the ACCELERATE study according to RVR. Mangia et al. random-
ized 283 patients to receive pegIFN-a2b 1.0 lg/kg and weight-
based RBV 1000–1200 mg to a standard 24-week regimen
(n = 70), or to a variable one where subjects were assigned to
be treated for 12 weeks if achieving an RVR (n = 133) or 24 weeks
if not (n = 80). Their overall rate of RVR was 63%. As shown inShiffman et al. Mangia et al. Dalgard et al.
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Fig. 3. The sustained virological response rates (SVR) obtained in randomized
controlled trials (Mangia et al. and Dalgard et al.) comparing 24-week and
short courses of pegIFN and RBV according to rapid virological response (RVR)
are shown. The colored bars show the response rates in patients who achieved
RVR. The different colors show the different genotypes and the duration of
therapy, short vs standard 24 weeks. The white bars at the bottom show the rates
of SVR in those who did not achieve RVR. The results are divided by genotype but
notably, all non-RVR patients were treated for 24 weeks. The results from the
ACCELERATE trial (Shiffman et al.), in which treatment duration was not
dependent on RVR, are depicted in the same way for comparison.
468 Journal of Hepatology 201Fig. 3, among patients achieving an RVR there was a small differ-
ence in the SVR rate favoring G2 in the shortened therapy groups
(10%), but the numbers were too small for a fair comparison
between the 24-week treatment arms. In patients not achieving
an RVR (24-week regimen), there was a larger difference in the
SVR rate between G2 and G3 (31%), although again, the number
of patients in the G3 group (n = 9) was quite small [16]. Dalgard
et al. treated 428 patients with pegIFN-a2b 1.5 lg/kg and
weight-based RBV 800–1400 mg, and randomized 298 achieving
RVR (RVR rate 71%, 302/428) to a shortened course of 14 vs
24 weeks of therapy. The overall rates of SVR in the intention-
to-treat analysis for G2 and G3 were 70% and 66%, respectively.
Among patients with an RVR, the differences by genotype were
small comparing patients treated for the same duration (Fig. 3).
In contrast, in patients not achieving an RVR but treated with a
full 24-week course there was a notable difference of 19% in
the rate of SVR between G2 and G3 [17]. These data all show a
similar trend; rates of SVR are higher in G2 than G3 but for
patients achieving an RVR, the differences are less striking.
A second meta-analysis looked speciﬁcally at duration of ther-
apy in G2/3. Slavenburg et al. found that pooling of data from 5
trials (including 3 unpublished studies) with a total of 785
patients, who were randomized after the achievement of an
RVR, failed to demonstrate any difference in SVR between
standard- and short-duration regimens (83% and 82%, respec-
tively; RR: 1.00, 95% CI: 0.92–1.09). However, for this analysis,
patients with G2/3 were combined. A subanalysis of patients with
G3 alone showed a trend toward superiority of 24 weeks of
therapy, while for patients with G2, despite relatively small
numbers, there was no difference between standard and
shortened therapy [18].
Taken together, all of the above evidence points out that a reg-
imen of 24 weeks of therapy is appropriate for the majority of
patients with chronic hepatitis C (CHC) caused by G2/G3. Short-
ened courses may be offered to G2 patients achieving an RVR,
irrespective of the viral load, as it is a cost-effective approach
[17] and retreatment of relapsers for 24 weeks is not compro-
mised [19]. However, the data suggest it may not be prudent to
shorten therapy in patients bearing other factors associated with
failure to achieve SVR (i.e. age >45 years,PF3 ﬁbrosis). Treatment
for G3 is less straightforward. Viral load seems to be more rele-
vant in G3 than G2, as it affects both the rate of RVR [20] and
increases the chance of relapse [21]. Patients who achieve RVR
do well with a standard 24-week course of therapy and some
data suggest that treatment can be shortened in such individuals.
For those who do not achieve RVR, particularly if starting with a
high viral load, rates of SVR approach those for G1 and thus it
seems prudent not to consider this subgroup of G3 as ‘easy to
treat’. Whether these patients may beneﬁt from an extended
course of 48 weeks, just as with G1 infection, remains an open
question.Extended or intensive courses of therapy in genotypes 2 and 3
The need to treat G2 and G3 patients for 48 weeks (extended
therapy) or with weight-based RBV (intensive therapy) was
shown to be unnecessary in the registration study of
pegIFN-a2a by Hadziyannis et al. The authors randomized 492
patients to any of four arms including pegIFN-a2a 180 mg/week:
with 800 mg/day of RBV for 24 or 48 weeks, and with1 vol. 55 j 466–473
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1000–1200 mg/day (weight-based) for 24 or 48 weeks. There was
no difference in the rate of SVR among the four groups (Fig. 4).
Stratiﬁcation according to the presence of low or high viral load
(cut-off value: 600,000 IU/ml), or to the presence/absence of
bridging ﬁbrosis and cirrhosis also failed to identify any differ-
ences. Thus, this landmark study showed no beneﬁt from an
extended or intensive therapy in those infected with G2/G3 [3].
However, in an interesting abstract from the same authors, the
same data were re-analyzed for patients without an RVR, and it
was found that extended/intensiﬁed therapy with weight-based
RBV for 48 weeks offered a 9% gain in SVR over the standard
24 week, low-dose ribavirin regimen (Fig. 4). This was accom-
plished by a remarkable lowering of the relapse rate: 25% for
the 24-week arms vs 13% and 4% in the 48-week arms with
800 mg and weight-based RBV, respectively [22]. Unfortunately,
given that the trial achieved a high rate of RVR (75%), the number
of patients included in this analysis was small (<40 patients per
group) and the differentiation of G3 from G2 patients was not
possible. Nevertheless, the 76% rate of SVR observed in non-
RVR patients with extended and intensive therapy contrasts with
the 39–53% observed in the ACCELERATE trial in the 24-week,
800 mg of RBV regimen. Data from the NORDynamIC trial also
suggested a beneﬁt to higher RBV dosing. They found a gradient
effect with higher plasma concentration of RBV being associated
with higher rates of SVR, and levels >2 mg/L at day 29 of therapy
as an independent predictor of SVR [23]. A post-hoc analysis com-
bining data from two clinical trials from Scandinavia and Italy
(using weight-based RBV) showed that a RBV dose P15 mg/kg
during the ﬁrst 4 weeks of antiviral therapy was associated with
a higher rate of RVR, and this was particularly evident in patients
with G3 infection. Moreover, the maintenance of the full dose
throughout treatment was an independent predictor of SVR in
patients with shortened therapy (12 or 14 weeks) [24]. Collec-
tively these data make a case for using weight-based ribavirin,
particularly if shortened therapy is to be considered.0
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Fig. 4. Results from the pegIFN-a2a registration trial (Hadziyannis et al.)
demonstrating the lack of difference in sustained virological response (SVR)
according to length of therapy (between 24-week and 48-week) and RBV dose
(standard vs weight-based), in genotype 2 and genotype 3 patients. Reanalysis
of the same data from Willems et al. demonstrates the superior SVR rate from the
extended/intensive regimen (48-week and weight-based RBV) in those who failed
to achieve a rapid virological response.
Journal of Hepatology 201A recent clinical trial fromMangia et al. examined the length of
therapy according to achievement of RVR. Patients with G3 infec-
tion were randomized to a standard 24-week regimen (pegIFN-
a2b 1.5 lg/kg and weight-based RBV 1000–1200 mg) or to a
variable duration therapy of 12 or 36 weeks according to the pres-
ence or absence of RVR, respectively. In patients with an RVR, a
difference in SVR could not be demonstrated between patients
receiving the standard (82%) or 12-week (83%) regimens, although
a non-signiﬁcant higher rate of relapse was observed in patients
who received the shorter course (10% and 15%, respectively).
When considering patients without an RVR, extended therapy
(36-week) yielded a 10% increase in SVR (62% vs 52%) when com-
pared to the standard 24 weeks, although this did not reach statis-
tical signiﬁcance. Notably, this difference was not related to a
decrease in the relapse rate (36-week: 20%, 24-week: 18%). Base-
line viral load did not affect the rate of SVR in patients with an
RVR, but unfortunately this was not reported for those without
an RVR [20]. Although this well-conducted study sheds light into
the role of RVR for tailoring the length of treatment in G3 patients,
their non-inferiority design is only appropriate for RVR patients
(12- vs 24-week comparison), but not for the non-RVR group
(24- vs 36-week comparison), thereby, limiting the interpretation
of these exciting results. Of note, the SVR rate in non-RVR was
similar to that observed in G1 patients, and a clinicallymeaningful
increase to 62% was observed by prolonging therapy by 12 weeks.
The question remains as to whether a 48-week regimen in
patients with known risk factors for therapeutic failure can
decrease the relapse rate and further increase SVR.
The proposal to extend and intensify treatment (48 weeks
with weight-based RBV) in patients with G3 infection who do
not achieve RVR needs to be conﬁrmed by prospective studies.
These would need to stratify by at least two of the major adverse
factors for an SVR, ﬁbrosis stage, and baseline viral load [3,14], as
they can signiﬁcantly inﬂuence the outcome of antiviral therapy.
This was shown when re-analyzing the experience of a Canadian
multi-centered and non-randomized study in which the rate of
SVR in G3 patients with cirrhosis was 17%, in comparison
to >60% in the absence of cirrhosis [25]. The ongoing
EXACT-R(3) is a randomized clinical trial exploring the beneﬁt
of an extended regimen (48- vs 24-week) of pegIFN-a2b, using
weight-based RBV, with proper stratiﬁcation for ﬁbrosis and
baseline viral load. The study will also clarify other predictive fac-
tors of response, such as ethnicity and metabolic factors. The
results of this trial are eagerly awaited to clarify the management
of G3 HCV, particularly given that the new direct-acting antivirals
appear to have minimal activity in this population.Why is G3 more difﬁcult to treat than G2?
Genotype is a marker of interferon responsiveness
The exogenous administration of alpha interferon enhances the
innate and adaptive immune response against the virus, mainly
by boosting the induction of interferon-stimulated genes (ISG)
through activation of the Janus kinase transducers and activators
of transcription (Jak/STAT) pathway. ISG promote antiviral, anti-
proliferative, and immunoregulatory signals in the host cell that
can potentially lead to eradication of HCV [26,27]. However,
intracellular pathways and their effector mechanisms need to
be very ﬁnely tuned for the therapy to be effective.1 vol. 55 j 466–473 469
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Microarray analysis from pre-treatment liver biopsies has
shown that that non-responders to pegIFN-based therapy have
increased basal expression of hepatic ISG prior to treatment
[28,29]. Near maximal ISG expression prior to therapy prevents
further induction with pegIFN treatment [30,31]. A recent study
from Chen et al. showed that ISG pre-activation is a stronger pre-
dictor of outcome than viral genotype. Patients with G1 infection
are more likely to have the non-responder phenotype (ISG pre-
activation) than those with G2/G3, however, the relatively
uncommon G2/G3 non-responders have the identical gene
expression signature as non-responders with G1 [32]. Why G1
HCV more commonly promotes ISG pre-activation is not yet
understood but likely underlies the genotypic difference in treat-
ment response.
Careful analyses of very early viral kinetics from clinical trials
have shed light on the mechanisms of action of interferon alpha
and the differential effects seen in different HCV genotypes.
Changes in HCV RNA levels occur in a biphasic pattern with a
steep decrease in the ﬁrst 24–48 h after the initial dose of inter-
feron, with a more gradual reduction thereafter. The initial drop
is thought to be related to inhibition of viral replication and clear-
ance of free circulating virus; whereas the slower second phase
represents the rate of clearance of infected hepatocytes [33].
Non-responders to pegIFN show little or no decrease in viral load
from the start of therapy, suggesting an intrinsic resistance to the
antiviral activity of interferon alpha. The decreased response
observed in the ﬁrst and second phases of viral kinetics, continues
with lack of RVR and culminates in failure to eradicate the virus.
The gene expression pattern typically induced by each viral
genotype correlates well with the responsiveness to interferon.
Comparison of kinetics during interferon monotherapy showed
that G2 patients have a faster ﬁrst and second phase decline than
those with G1 infection [34]. Similar results were later repro-
duced with pegIFN treatment with G3 infection, showing an
intermediate susceptibility between G2 and G1 [35]. Rather than
expressing true interferon resistance, it seems that HCV geno-
types are more or less likely to promote the ISG pre-activation
phenotype (G1>G4>G3>>G2), which ultimately prevents hepato-
cytes from responding to pegIFN treatment leading to poor early
viral kinetics and ultimately to failure to clear virus.
The recent identiﬁcation of single nucleotide polymorphisms
(SNP) upstream of the IL28B gene that are associated with
response to pegIFN-based therapy is a landmark observation.
Multiple groups have independently shown that patients with
the favorable SNP have at least a 2.5-fold increase in the rate of
SVR. The closest gene to the identiﬁed SNP is known as IL28B
or interferon lambda 3 (IFN-k3), a type 3 interferon that signals
via the JAK-STAT pathway to induce ISG but uses a different
receptor than interferon-alpha or beta [36]. The SNP was also
shown to be signiﬁcantly more prevalent in patients who sponta-
neously clear HCV [37]. The IL28B genotype could at least in part
explain the pre-activation of ISG in non-responders, as those with
the unfavorable IL28B genotype show increased levels of intra-
hepatic ISG [38,39].
To date most of the data on the IL28B SNP come from patients
with G1 infection [40,41]. Mangia et al. studied this polymor-
phism in G2/G3 patients from their randomized clinical trial
comparing short and 24-week therapy according to RVR. A
positive effect on SVR was observed in patients bearing the favor-
able IL28B allele, although it was attenuated when compared to
G1. This related to the high RVR rate (63%), as the effect was only470 Journal of Hepatology 201seen in patients not achieving an RVR. Surprisingly, in the non-
RVR group patients, the CT variant showed an intermediate effect
between CC and TT (SVR: 67%, 87% and 29%, respectively).
Although their reduced sample of G3 patients limited interpreta-
tion of the data, the prognostic usefulness of IL28B was higher for
G3 (OR: 5.5, 95% CI = 1.2–25) than for G2 (OR: 2.3, 95% CI = 1.2–
4.5) [42].
It may be that certain viral genotypes are inherently more
likely to induce ISG pre-activation and the likelihood of this
occurrence is modiﬁed by the presence of the IL28B SNP. Once
present, ISG pre-activation is the strongest predictor of ultimate
treatment outcome, regardless of the viral genotype or the SNP
[43,44]. Because liver biopsy is invasive and gene expression
analysis is not widely available, using ISG pre-activation as a pre-
dictor of response is rather impractical and other pre and on-
treatment markers have been examined, but will need further
validation before becoming clinically useful. Until better markers
are validated, RVR remains the best predictor.Do insulin resistance and steatosis contribute to poor
outcome in genotype 3?
The metabolic syndrome clusters disease traits related to insulin
resistance (i.e. hyperglycemia/hyperinsulinemia, adiposity, dysli-
pidemia, arterial hypertension), to predict an increased risk of
cardiovascular morbidity and type-2 diabetes mellitus [45,46].
Obesity [47], insulin resistance [48], impaired fasting glucose,
and diabetes mellitus [49–52] have been strongly associated with
chronic HCV infection, and their presence predicts decreased like-
lihood for an SVR with pegIFN and RBV therapy [53–59]. Further,
viral eradication is followed by an improvement in insulin resis-
tance [60], and a decreased risk for future type 2 diabetes melli-
tus [61]. Although, most evidence comes from trials assessing G1
patients, obesity (BMI P30 kg/m2) and insulin resistance have
also been shown to impair the rate of SVR in G2/G3 infection
[19,62].
Liver steatosis is now recognized as an additional feature of
the metabolic syndrome. It is commonly found in patients with
CHC [63], but seems to be more prevalent in patients with G3
infection [64]. Importantly, the presence of steatosis, indepen-
dent of other metabolic risk factors, has also been associated with
treatment non-response [59,65–67]. In the ACCELERATE trial,
liver steatosis was associated with a decreased rate of SVR (60%
vs 75%, in the 24-week arm), and was also reported to negatively
impact treatment outcome in the NORDynamIC study [14,15]. In
an open-label study including G2/G3 CHC, Zeuzem et al. found
that steatosis affected the rate of SVR mostly in G3 patients
[21]. It has also been associated with accelerated ﬁbrosis in G3
patients [68]. Notably, steatosis in G3 infection disappears
entirely after viral eradication, suggesting that it is induced
directly by the virus [65].
Traditionally, steatosis in G3 has been attributed directly to
the virus itself, whereas in non-G3 it is thought to be caused by
host metabolic factors [69]. Such a strict dichotomy may be too
simplistic. Unlike type 2 diabetes mellitus and the metabolic syn-
drome, in HCV infection the association between liver steatosis
and insulin resistance is not straightforward for any genotype.
Experimental and clinical research have shown that independent
of viral genotype, the HCV lifecycle interacts directly with the
glucose and lipid machinery of the cell (i.e. insulin receptor sub-1 vol. 55 j 466–473
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strate, apolipoproteins, sterol regulatory element-binding protein
or SREBP1c, microsomal triglyceride transfer protein or MTP, per-
oxisome proliferator-activated receptors) [67–75] that may ulti-
mately cause either insulin resistance or liver steatosis alone
(i.e. independently of insulin resistance). Studies with the
euglycemic-hyperinsulinemic clamp have shown both hepatic
and particularly systemic insulin resistance in patients with
CHC (G1 and G3) without any metabolic risk factors and irrespec-
tive of the presence of hepatic steatosis [76,77]. Thus, it is
possible that steatosis in HCV infection is more related to a
viral-induced defect in the synthesis and intracellular transport
of triglycerides (induction of SREBP1c and decrease in MTP,
respectively) [73], than to insulin resistance. The mechanisms
for these effects may even differ between genotypes [75], how-
ever, because of the myriad of complex host–viral metabolic
interactions, this may be difﬁcult to tease apart.
The steatogenic nature of G3 may partially account for the
poorer responses observed with G3 than G2, although in patients
with risk factors for the metabolic syndrome, insulin resistance
may also play a major role. As both conditions ﬁnally affect the
response to pegIFN and RBV, they may be considered before initi-
ating therapy. Whether insulin sensitizers may be useful to
improve response in some G3 patients remains an open question.
Clarifying how metabolic abnormalities impair the interferon
response andwhy G3 is steatogenic will hopefully shed some light
on the differences in response between the ‘favorable’ genotypes.Conclusions
The grouping of G2 and G3 under the label of ‘easy to treat’
genotypes was an unfortunate consequence of their under-RVR(-)
RVR(+)
Consider if: Age ≥45, B
RVR(+)
RVR(-)
Consider if: Age ≥45, B
              IR/Steatosis ?
Consider if unfavorable
Trials ongoing
G2
G3
Fig. 5. Algorithm for addressing length of therapy in genotype 2 (G2) and genotype
show proposed strategies drawn from available evidence, but for which randomized cli
should be considered within these negative parameters remains in question. In patients w
of sustained virological response, and trials are ongoing. This may be especially true for
body mass index; F, ﬁbrosis; VL, viral load; IR, insulin resistance.
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the current standard of care. A careful examination of data from
many trials shows fairly clearly that patients infected with G3 do
not respond as well as those with G2 infection to pegIFN-based
therapy. Patients with G3 infection sometimes behave more like
those with G1 infection, whereas G2 is almost universally a truly
‘easy to treat’ genotype. What underlies this difference is less
clear. The different genotypes may be intrinsically more or less
sensitive to the effects of interferon, or alternatively, and seem-
ingly more likely, the different genotypes may differentially
affect the ability of the host liver cells to respond to exogenous
interferon, an effect that may be modulated by the host genotype
(IL28B SNP). Why certain genotypes are more likely to induce ISG
pre-activation and/or hepatic steatogenesis, both of which impair
interferon responses, is not well understood but may explain the
differences in treatment outcome across genotypes.
Fortunately, early viral responses, and in particular the
achievement of an RVR, are very helpful in predicting the ulti-
mate outcome of therapy. For patients who achieve an RVR, the
consideration of shortened therapy (16 weeks) may be reason-
able, even though SVR rates are likely still slightly higher with
24 weeks of therapy. However, the presence of poor prognostic
factors, such as advanced ﬁbrosis, obesity, increased age, and
probably insulin resistance and liver steatosis in the speciﬁc case
of G3, may discourage a shortened course of therapy. Whether
extending therapy (48 weeks) in patients who do not achieve
an RVR would be beneﬁcial, particularly in those with G3 and/
or poor prognostic factors will have to be formally assessed in
clinical trials, but seems like an attractive option. New data sug-
gest a prognostic role for IL28B polymorphisms mostly in G3
patients not achieving an RVR, and these could also be considered
for improved tailoring of therapy (Fig. 5). Although the initial48 wk
16 wk
24 wkMI ≥30, ≥F3
16 wk
24 wkMI ≥30, ≥F3
 IL28b?
3 (G3) infection, according to rapid virological response (RVR). Broken arrows
nical trials are lacking or currently ongoing. Whether the presence of IR/steatosis
ithout an RVR it is likely that extending therapy to 48 weeks may increase the rate
patients with unfavorable IL28B genotypes (CT and especially TT variants). BMI,
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trials found low-dose RBV (800 mg) to be adequate in G2/G3,
most subsequent data suggest that weight-based RBV is more
appropriate. Weight-based dosing is particularly important if a
shortened course of therapy is to be considered. Although we
are on the cusp of a new era in HCV therapy, the ﬁrst generation
of direct acting antivirals have limited or no activity against G3
infection. As such, pegIFN and RBV will remain the standard of
care for G3 infection for the foreseeable future. As a result,
researchers will need to focus on better understanding the mech-
anisms impairing interferon-responses in G3 infection and clini-
cians will have to tailor current therapy to optimize treatment
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